These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36791206)

  • 21. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.
    Maccari M; Baek C; Caccese M; Mandruzzato S; Fiorentino A; Internò V; Bosio A; Cerretti G; Padovan M; Idbaih A; Lombardi G
    Oncologist; 2024 Apr; 29(4):289-302. PubMed ID: 38048782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma.
    Zhou S; Huang Y; Chen Y; Liu Y; Xie L; You Y; Tong S; Xu J; Jiang G; Song Q; Mei N; Ma F; Gao X; Chen H; Chen J
    Nat Commun; 2023 Jan; 14(1):435. PubMed ID: 36702831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
    Brempelis KJ; Cowan CM; Kreuser SA; Labadie KP; Prieskorn BM; Lieberman NAP; Ene CI; Moyes KW; Chinn H; DeGolier KR; Matsumoto LR; Daniel SK; Yokoyama JK; Davis AD; Hoglund VJ; Smythe KS; Balcaitis SD; Jensen MC; Ellenbogen RG; Campbell JS; Pierce RH; Holland EC; Pillarisetty VG; Crane CA
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toosendanin Exerts an Anti-Cancer Effect in Glioblastoma by Inducing Estrogen Receptor β- and p53-Mediated Apoptosis.
    Cao L; Qu D; Wang H; Zhang S; Jia C; Shi Z; Wang Z; Zhang J; Ma J
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
    Koch MS; Zdioruk M; Nowicki MO; Griffith AM; Aguilar E; Aguilar LK; Guzik BW; Barone F; Tak PP; Tabatabai G; Lederer JA; Chiocca EA; Lawler S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor.
    Gao G; Liao W; Shu P; Ma Q; He X; Zhang B; Qin D; Wang Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37591632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types.
    Khalsa JK; Cheng N; Keegan J; Chaudry A; Driver J; Bi WL; Lederer J; Shah K
    Nat Commun; 2020 Aug; 11(1):3912. PubMed ID: 32764562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
    Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
    PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
    Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
    Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
    Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
    [No Abstract]   [Full Text] [Related]  

  • 32. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy.
    Chang Y; Cai X; Syahirah R; Yao Y; Xu Y; Jin G; Bhute VJ; Torregrosa-Allen S; Elzey BD; Won YY; Deng Q; Lian XL; Wang X; Eniola-Adefeso O; Bao X
    Nat Commun; 2023 Apr; 14(1):2266. PubMed ID: 37080958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
    Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
    PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recruiting T-Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co-Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage-Membrane-Camouflaged Nanovesicles.
    Xu X; Zhang Z; Du J; Xue Y; Chen X; Zhang J; Yang X; Chang D; Xie J; Ju S
    Adv Mater; 2023 Jun; 35(25):e2209785. PubMed ID: 37101060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy.
    Zhang Z; Wang G; Zhong K; Chen Y; Yang N; Lu Q; Yuan B; Wang Z; Li H; Guo L; Zhang R; Wu Z; Zheng M; Zhao S; Tang X; Shao B; Tong A
    J Transl Med; 2023 Jan; 21(1):23. PubMed ID: 36635683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model.
    Murty S; Haile ST; Beinat C; Aalipour A; Alam IS; Murty T; Shaffer TM; Patel CB; Graves EE; Mackall CL; Gambhir SS
    Oncoimmunology; 2020 May; 9(1):1757360. PubMed ID: 32923113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma.
    Yeo AT; Shah R; Aliazis K; Pal R; Xu T; Zhang P; Rawal S; Rose CM; Varn FS; Appleman VA; Yoon J; Varma H; Gygi SP; Verhaak RGW; Boussiotis VA; Charest A
    Cancer Immunol Res; 2023 May; 11(5):629-645. PubMed ID: 36881002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration.
    Uneda A; Kurozumi K; Fujimura A; Fujii K; Ishida J; Shimazu Y; Otani Y; Tomita Y; Hattori Y; Matsumoto Y; Tsuboi N; Makino K; Hirano S; Kamiya A; Date I
    Acta Neuropathol Commun; 2021 Feb; 9(1):29. PubMed ID: 33618763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
    Wang C; Yu M; Zhang W
    Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.